Skip to main content

Articles

Page 1 of 99

  1. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf

    Citation: Breast Cancer Research 2021 23:28

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:20

  2. Patients diagnosed with metastatic breast cancer have poor outcome with a median survival of approximately 2 years. While novel therapeutic options are urgently needed, the great majority of breast cancer rese...

    Authors: Jenny Stenström, Ingrid Hedenfalk and Catharina Hagerling

    Citation: Breast Cancer Research 2021 23:27

    Content type: Research article

    Published on:

  3. Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lack...

    Authors: Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch…

    Citation: Breast Cancer Research 2021 23:26

    Content type: Research article

    Published on:

  4. Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of D...

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves

    Citation: Breast Cancer Research 2021 23:25

    Content type: Research article

    Published on:

  5. Estimates of contralateral breast cancer (CBC) risk in the modern treatment era by year of diagnosis and characteristics of the first breast cancer are needed to assess the impact of recent advances in breast ...

    Authors: Cody Ramin, Diana R. Withrow, Brittny C. Davis Lynn, Gretchen L. Gierach and Amy Berrington de González

    Citation: Breast Cancer Research 2021 23:24

    Content type: Research article

    Published on:

  6. Cyclooxygenase 2 (COX-2) promotes stemness in triple negative breast cancer (TNBC), highlighting COX-2 as a promising therapeutic target in these tumors. However, to date, clinical trials using COX-2 inhibitor...

    Authors: Jun Tian, Vivian Wang, Ni Wang, Baharak Khadang, Julien Boudreault, Khldoun Bakdounes, Suhad Ali and Jean-Jacques Lebrun

    Citation: Breast Cancer Research 2021 23:23

    Content type: Research article

    Published on:

  7. The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have recent...

    Authors: Parichoy Pal Choudhury, Mark N. Brook, Amber N. Hurson, Andrew Lee, Charlotta V. Mulder, Penny Coulson, Minouk J. Schoemaker, Michael E. Jones, Anthony J. Swerdlow, Nilanjan Chatterjee, Antonis C. Antoniou and Montserrat Garcia-Closas

    Citation: Breast Cancer Research 2021 23:22

    Content type: Short report

    Published on:

  8. FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distri...

    Authors: Silvana Mouron, Luis Manso, Eduardo Caleiras, Jose L. Rodriguez-Peralto, Oscar M. Rueda, Carlos Caldas, Ramon Colomer, Miguel Quintela-Fandino and Maria J. Bueno

    Citation: Breast Cancer Research 2021 23:21

    Content type: Research article

    Published on:

  9. Breast cancer in young adults has been implicated with a worse outcome. Analyses of genomic traits associated with age have been heterogenous, likely because of an incomplete accounting for underlying molecula...

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf

    Citation: Breast Cancer Research 2021 23:20

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:28

  10. Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflamm...

    Authors: Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko and Michelle Janelsins

    Citation: Breast Cancer Research 2021 23:19

    Content type: Research article

    Published on:

  11. To evaluate weight change patterns over time following the diagnosis of breast cancer and to examine the association of post-diagnosis weight change and survival outcomes in Black and White patients.

    Authors: Lihua Shang, Masaya Hattori, Gini Fleming, Nora Jaskowiak, Donald Hedeker, Olufunmilayo I. Olopade and Dezheng Huo

    Citation: Breast Cancer Research 2021 23:18

    Content type: Research article

    Published on:

  12. In breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and surv...

    Authors: Anna L. V. Johansson, Cassia B. Trewin, Irma Fredriksson, Kristin V. Reinertsen, Hege Russnes and Giske Ursin

    Citation: Breast Cancer Research 2021 23:17

    Content type: Research article

    Published on:

  13. The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing brea...

    Authors: Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman and Andreas H. Hielscher

    Citation: Breast Cancer Research 2021 23:16

    Content type: Research article

    Published on:

  14. It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune ...

    Authors: Thomas E. Rohan, Rhonda Arthur, Yihong Wang, Sheila Weinmann, Mindy Ginsberg, Sherene Loi and Roberto Salgado

    Citation: Breast Cancer Research 2021 23:15

    Content type: Research article

    Published on:

  15. There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus...

    Authors: Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai and Sarah Mougalian

    Citation: Breast Cancer Research 2021 23:14

    Content type: Research article

    Published on:

  16. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Zaklina Kovacevic, Des R. Richardson, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm…

    Citation: Breast Cancer Research 2021 23:13

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2020 22:75

  17. MicroRNAs have been reported to participate in tumorigenesis, treatment resistance, and tumor metastasis. Novel microRNAs need to be identified and investigated to guide the clinical prognosis or therapy for b...

    Authors: Chong Chen, Yundi Pan, Lipeng Bai, Huilin Chen, Zhaojun Duan, Qin Si, Ruizhe Zhu, Tsung-Hsien Chuang and Yunping Luo

    Citation: Breast Cancer Research 2021 23:12

    Content type: Research article

    Published on:

  18. Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled recep...

    Authors: Xuanmao Jiao, Min Wang, Zhao Zhang, Zhiping Li, Dong Ni, Anthony W. Ashton, Hsin-Yao Tang, David W. Speicher and Richard G. Pestell

    Citation: Breast Cancer Research 2021 23:11

    Content type: Research article

    Published on:

  19. Basal-like breast cancers (BLBCs) are a leading cause of cancer death due to their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a dysfunctional BRCA1. Although most BRCA1-...

    Authors: Feng Bai, Shiqin Liu, Xiong Liu, Daniel P. Hollern, Alexandria Scott, Chuying Wang, Lihan Zhang, Cheng Fan, Li Fu, Charles M. Perou, Wei-Guo Zhu and Xin-Hai Pei

    Citation: Breast Cancer Research 2021 23:10

    Content type: Research article

    Published on:

  20. Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multice...

    Authors: Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi…

    Citation: Breast Cancer Research 2021 23:9

    Content type: Research article

    Published on:

  21. Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xe...

    Authors: Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero…

    Citation: Breast Cancer Research 2021 23:8

    Content type: Research article

    Published on:

  22. Invasive pleomorphic lobular carcinoma (PLC) of the breast is a subtype of invasive lobular cancer which compromises approximately 1% of all epithelial breast malignancies and is characterized by higher nuclea...

    Authors: Gregory M. Riedlinger, Sonali Joshi, Kim M. Hirshfield, Nicola Barnard and Shridar Ganesan

    Citation: Breast Cancer Research 2021 23:7

    Content type: Research article

    Published on:

  23. Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpin...

    Authors: Amy E. McCart Reed, Lauren Kalinowski, Peter T. Simpson and Sunil R. Lakhani

    Citation: Breast Cancer Research 2021 23:6

    Content type: Review

    Published on:

  24. Existence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BC...

    Authors: Yu-Mei Liao, Ya-Hui Wang, Jung-Tung Hung, Yu-Ju Lin, Yen-Lin Huang, Guo-Shiou Liao, Ya-Ling Hsu, Jen-Chien Wu and Alice L. Yu

    Citation: Breast Cancer Research 2021 23:5

    Content type: Research article

    Published on:

  25. NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric ...

    Authors: Karen D. Howarth, Tashfina Mirza, Susanna L. Cooke, Suet-Feung Chin, Jessica C. Pole, Ernest Turro, Matthew D. Eldridge, Raquel Manzano Garcia, Oscar M. Rueda, Chris Boursnell, Jean E. Abraham, Carlos Caldas and Paul A. W. Edwards

    Citation: Breast Cancer Research 2021 23:3

    Content type: Research article

    Published on:

  26. The H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer, but are operator-de...

    Authors: Katherine Sanchez, Isaac Kim, Brie Chun, Joanna Pucilowska, William L. Redmond, Walter J. Urba, Maritza Martel, Yaping Wu, Mary Campbell, Zhaoyu Sun, Gary Grunkemeier, Shu Ching Chang, Brady Bernard and David B. Page

    Citation: Breast Cancer Research 2021 23:2

    Content type: Research article

    Published on:

  27. Endocrine therapy resistance is a hallmark of advanced estrogen receptor (ER)-positive breast cancer. In this study, we aimed to determine acquired genomic changes in endocrine-resistant disease.

    Authors: Nolan Priedigkeit, Kai Ding, William Horne, Jay K. Kolls, Tian Du, Peter C. Lucas, Jens-Uwe Blohmer, Carsten Denkert, Anna Machleidt, Barbara Ingold-Heppner, Steffi Oesterreich and Adrian V. Lee

    Citation: Breast Cancer Research 2021 23:1

    Content type: Research article

    Published on:

  28. Tumour-infiltrating lymphocytes (TILs) are of important prognostic and predictive value in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC),...

    Authors: Christine Lundgren, Pär-Ola Bendahl, Maria Ekholm, Mårten Fernö, Carina Forsare, Ute Krüger, Bo Nordenskjöld, Olle Stål and Lisa Rydén

    Citation: Breast Cancer Research 2020 22:140

    Content type: Research article

    Published on:

  29. Lysosomal cysteine protease cathepsin V has previously been shown to exhibit elevated expression in breast cancer tissue and be associated with distant metastasis. Research has also identified that cathepsin V...

    Authors: Naphannop Sereesongsaeng, Sara H. McDowell, James F. Burrows, Christopher J. Scott and Roberta E. Burden

    Citation: Breast Cancer Research 2020 22:139

    Content type: Research article

    Published on:

  30. Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be associated with breast cancer risk, but previous studies of the association are equivocal and limited by incomplete bl...

    Authors: Gordon P. Watt, Janice Sung, Elizabeth A. Morris, Saundra S. Buys, Angela R. Bradbury, Jennifer D. Brooks, Emily F. Conant, Susan P. Weinstein, Despina Kontos, Meghan Woods, Sarah V. Colonna, Xiaolin Liang, Matthew A. Stein, Malcolm C. Pike and Jonine L. Bernstein

    Citation: Breast Cancer Research 2020 22:138

    Content type: Research article

    Published on:

  31. Survival rates for breast cancer (BC) have improved, but quality of life post-diagnosis/treatment can be adversely affected, with survivors reporting a constellation of psychoneurological symptoms (PNS) includ...

    Authors: Areej A. Alhareeri, Kellie J. Archer, Han Fu, Debra E. Lyon, R. K. Elswick Jr, Debra L. Kelly, Angela R. Starkweather, Lynne W. Elmore, Yahya A. Bokhari and Colleen K. Jackson-Cook

    Citation: Breast Cancer Research 2020 22:137

    Content type: Research article

    Published on:

  32. Breast cancers acquire aggressive capabilities via epithelial to mesenchymal transition (EMT), in which various integrins/integrin-linked kinase signalling are upregulated.

    Authors: Razan Wafai, Elizabeth D. Williams, Emma de Souza, Peter T. Simpson, Amy E. McCart Reed, Jamie R. Kutasovic, Mark Waltham, Cameron E. Snell, Tony Blick, Erik W. Thompson and Honor J. Hugo

    Citation: Breast Cancer Research 2020 22:136

    Content type: Research article

    Published on:

  33. The lack of specificity and high degree of false positive and false negative rates when using mammographic screening for detecting early-stage breast cancer is a critical issue. Blood-based molecular assays th...

    Authors: Claudia Fredolini, Khyatiben V. Pathak, Luisa Paris, Kristina M. Chapple, Kristine A. Tsantilas, Matthew Rosenow, Tony J. Tegeler, Krystine Garcia-Mansfield, Davide Tamburro, Weidong Zhou, Paul Russo, Samuele Massarut, Francesco Facchiano, Claudio Belluco, Ruggero De Maria, Enrico Garaci…

    Citation: Breast Cancer Research 2020 22:135

    Content type: Research article

    Published on:

  34. Inflammatory breast cancer (IBC) is a rare but aggressive carcinoma characterized by severe erythema and edema of the breast, with many patients presenting in advanced metastatic disease. The “inflammatory” na...

    Authors: Sandra V. Fernandez, Alexander W. MacFarlane IV, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli and Kerry S. Campbell

    Citation: Breast Cancer Research 2020 22:134

    Content type: Research article

    Published on:

  35. Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of...

    Authors: Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon and Joan S. Brugge

    Citation: Breast Cancer Research 2020 22:132

    Content type: Research article

    Published on:

  36. We aimed to examine the safety and efficacy of bevacizumab and carboplatin in patients with breast cancer brain metastases.

    Authors: Jose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca S. Gelman, Bryan P. Schneider, Rachel A. Freedman, Jerry Younger, Marco C. Pinho, A. Gregory Sorensen, Elizabeth R. Gerstner, Gordon Harris, Ian E. Krop, Daniel Morganstern, Jessica Sohl, Jiani Hu, Elizabeth Kasparian…

    Citation: Breast Cancer Research 2020 22:131

    Content type: Research article

    Published on:

  37. Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment...

    Authors: Kyung-Min Lee, Hyebin Lee, Dohyun Han, Woo Kyung Moon, Kwangsoo Kim, Hyeon Jeong Oh, Jinwoo Choi, Eun Hye Hwang, Seong Eun Kang, Seock-Ah Im, Kyung-Hun Lee and Han Suk Ryu

    Citation: Breast Cancer Research 2020 22:130

    Content type: Research article

    Published on:

  38. Menopausal hormone therapy (MHT) increases breast cancer (BC) risk, but cohort studies largely consider use only at enrollment. Evidence is limited on how changes in MHT use alter the magnitude of risk, and wh...

    Authors: Shao-Ming Wang, Ruth M. Pfeiffer, Gretchen L. Gierach and Roni T. Falk

    Citation: Breast Cancer Research 2020 22:129

    Content type: Research article

    Published on:

  39. Extracellular vesicles (EVs) are small membrane particles that contribute to cancer progression and metastases by transporting biologically significant proteins and nucleic acids. They may also serve as biomar...

    Authors: Kimberly R. Jordan, Jessica K. Hall, Troy Schedin, Michelle Borakove, Jenny J. Xian, Monika Dzieciatkowska, Traci R. Lyons, Pepper Schedin, Kirk C. Hansen and Virginia F. Borges

    Citation: Breast Cancer Research 2020 22:128

    Content type: Research article

    Published on:

  40. Based on the androgen receptor (AR) expression, triple-negative breast cancer (TNBC) can be subdivided into AR-positive TNBC and AR-negative TNBC, also known as quadruple-negative breast cancer (QNBC). QNBC ch...

    Authors: Shristi Bhattarai, Geetanjali Saini, Keerthi Gogineni and Ritu Aneja

    Citation: Breast Cancer Research 2020 22:127

    Content type: Review

    Published on:

  41. Activating transcription factor-2 (ATF2), a member of the leucine zipper family of DNA binding proteins, has been implicated as a tumour suppressor in breast cancer. However, its exact role in breast cancer en...

    Authors: Athina Giannoudis, Mohammed Imad Malki, Bharath Rudraraju, Hisham Mohhamed, Suraj Menon, Triantafillos Liloglou, Simak Ali, Jason S. Carroll and Carlo Palmieri

    Citation: Breast Cancer Research 2020 22:126

    Content type: Research article

    Published on:

  42. CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal...

    Authors: Ozlen Balcioglu, Richard E. Heinz, David W. Freeman, Brooke L. Gates, Berhane M. Hagos, Evan Booker, Elnaz Mirzaei Mehrabad, Hyrum T. Diesen, Kishan Bhakta, Supraja Ranganathan, Masami Kachi, Mathias Leblanc, Peter C. Gray and Benjamin T. Spike

    Citation: Breast Cancer Research 2020 22:125

    Content type: Research article

    Published on:

  43. Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explo...

    Authors: Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes…

    Citation: Breast Cancer Research 2020 22:124

    Content type: Research article

    Published on:

  44. 27-Hydroxycholesterol (27HC) stimulates estrogen receptor-positive (ER+) breast cancer (BC) progression. Inhibiting the sterol 27-hydroxylase (CYP27A1) abrogates these growth-promoting effects of 27HC in mice....

    Authors: Siker Kimbung, Maria Inasu, Tor Stålhammar, Björn Nodin, Karin Elebro, Helga Tryggvadottir, Maria Ygland Rödström, Karin Jirström, Karolin Isaksson, Helena Jernström and Signe Borgquist

    Citation: Breast Cancer Research 2020 22:123

    Content type: Research article

    Published on:

  45. The role of nuclear receptors in both the aetiology and treatment of breast cancer is exemplified by the use of the oestrogen receptor (ER) as a prognostic marker and treatment target. Treatments targeting the...

    Authors: Tram B. Doan, Vanessa Cheung, Colin D. Clyne, Heidi N. Hilton, Natalie Eriksson, Morag J. Young, John W. Funder, George E. O. Muscat, Peter J. Fuller, Christine L. Clarke and J. Dinny Graham

    Citation: Breast Cancer Research 2020 22:122

    Content type: Research article

    Published on:

  46. Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, ty...

    Authors: Tejaswini P. Reddy, Roberto R. Rosato, Xiaoxian Li, Stacy Moulder, Helen Piwnica-Worms and Jenny C. Chang

    Citation: Breast Cancer Research 2020 22:121

    Content type: Review

    Published on:

  47. Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We ev...

    Authors: Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga…

    Citation: Breast Cancer Research 2020 22:120

    Content type: Research article

    Published on:

  48. Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent.

    Authors: Manon Cairat, Marie Al Rahmoun, Marc J. Gunter, Gianluca Severi, Laure Dossus and Agnès Fournier

    Citation: Breast Cancer Research 2020 22:118

    Content type: Research article

    Published on:

Annual Journal Metrics